logo
Plus   Neg
Share
Email

Sociétés Des Produits Nestlé To Acquire Aimmune For $34.50/Shr - Quick Facts

Aimmune Therapeutics Inc. (AIMT) announced definitive agreement for Socits des Produits Nestlé, S.A. to acquire the company for $34.50 per share in an all-cash
transaction, implying a fully-diluted equity value of $2.6 billion. The offer price represents 174% premium to Aimmune's closing price on August 28, 2020.

Socits des Produits Nestl, S.A. is a part of Nestlé Health Science and a
wholly owned subsidiary of Nestlé S.A. (NSTR.L).

The company expects this transaction to close in the fourth quarter of 2020.. Until that time, Aimmune will continue to operate as a separate and independent company.

This agreement was unanimously approved by all of the independent members of the Aimmune' Board.

Jayson Dallas, President and Chief Executive Officer of Aimmune, said, "This acquisition provides strong value for our shareholders and ensures a level of support for PALFORZIA and our pipeline that will further enhance their potential for patients around the world living with food allergies."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
Follow RTT